Thuốc Baclofen Ketamine Levodopa Pentazocine Propranolol Comments Digitalis Thông thường sau khi đột ngột rút tạo ra ảo giác, khóc, những thay đổi trong hình ảnh cơ thể, và mê sảng thường sau khi tăng liều Trong thời gian điều trị abovea Xem abovea Có thể được phổ biến không liều liên quan | 612 TEXTBOOK OF TRAUMATIC BRAIN INJURY TABLE 34-1. Psychiatric side effects of neurological drugs continued Symptom Medications Comments Paranoia Aggression Baclofen Ketamine Levodopa Pentazocine Propranolol Digitalis Asparaginase Bromocriptine Corticosteroids ACTH Amphetamines Indomethacin Propranolol Sulindac Bromocriptine Tranquilizers and hypnotics Levodopa Phenelzine Digitalis Carbamazepine Usually after sudden withdrawal Also produces hallucinations crying changes in body image and delirium Often after dosage increase During treatment See abovea See abovea May be common Not dose related See abovea Even at low doses Especially in elderly patients At any dose Reported in a few patients Not dose related may persist A release phenomenon See abovea May be separate from mania See abovea In children and adolescents Note. ACTH adrenocorticotropic hormone. aSame comments apply as for previous reactions on this drug. Source. Reprinted from Dubovsky SL Psychopharmacological Treatment in Neuropsychiatry in The American Psychiatric Press Textbook of Neuropsychiatry 2nd Edition. Washington DC American Psychiatric Press 1991 pp 694-695. Used with permission. TABLE 34-2. General principles of pharmacotherapy for patients with traumatic brain injuries Start low go slow Initiate treatment at doses lower than those used in patients without brain injuries and raise doses more slowly than in patients without brain injuries. Adequate therapeutic Although patients with brain injuries may be more sensitive to the side effects of many medications standard trial doses of such medication may be needed to treat adequately the neuropsychiatric problems of these patients. Continuous The need for continued treatment should be reassessed in an ongoing fashion and dose reduction or reassessment medication discontinuation should be attempted after achieving remission of target symptoms. Spontaneous recovery occurs and in such circumstances continued pharmacotherapy is unnecessary. Monitor .
